Skip to main content

Table 1 Patients characteristics

From: Relationship and prognostic importance of thyroid hormone and N-terminal pro-B-Type natriuretic peptide for patients after acute coronary syndromes: a longitudinal observational study

Characteristics All Survived throughout follow-up Died during follow-up p-value
n = 642 n = 607 n = 35
Age (years), mean ± SD 57.6 ± 9.5 57.4 ± 9.4 62.3 ± 9.2 0.004
Gender, n (%)     0.382
 Men 493 (76.8) 464 (76.4) 29 (82.9)  
 Women 149 (23.2) 143 (23.6) 6 (17.1)  
Body mass index, mean ± SD 29.8 ± 4.7 29.9 ± 4.7 29.0 ± 5.2 0.355
Diagnosis, n (%)     0.010
 Angina pectoris 159 (24.8) 149 (24.6) 10 (28.6)  
 Acute myocardial infarction 405 (63.1) 381 (62.8) 24 (68.6)  
 Previous myocardial infarction 78 (12.1) 77 (12.7) 1 (2.9)  
Angina pectoris class, n (%)     0.063
 I 143 (22.3) 138 (22.8) 5 (14.3)  
 II 214 (33.3) 196 (32.3) 18 (51.4)  
 III 18 (2.8) 16 (2.6) 2 (5.7)  
NYHA, n (%)     <0.001
 I 52 (8.1) 52 (8.6) -  
 II 468 (72.9) 451 (74.2) 17 (48.6)  
 III 122 (19.0) 104 (17.2) 18 (51.4)  
Hypertension, n (%)     0.001
 Grade 1 (mild) 39 (6.1) 37 (6.1) 2 (5.7)  
 Grade 2 (moderate) 354 (55.2) 345 (56.8) 9 (25.7)  
 Grade 3 (severe) 109 (17.0) 96 (15.8) 13 (37.1)  
Left ventricular ejection fraction %, mean ± SD 50.2 ± 9.0 50.5 ± 8.9 43.4 ± 8.2 0.001
Diabetes mellitus, n (%) 74 (11.5) 67 (11.1) 7 (20.0) 0.107
Nitrate, n (%) 255 (39.7) 233 (38.4) 22 (62.9) 0.004
Beta-blockers, n (%) 557 (86.8) 529 (87.3) 28 (80.0) 0.214
Angiotensin-converting enzyme inhibitors, n (%) 527 (82.1) 496 (81.8) 31 (88.6) 0.312
Diuretic, n (%) 101 (15.7) 92 (15.2) 9 (25.7) 0.096
N-terminal pro-B-Type natriuretic peptide (ng/L), median (interquartile ranges) 328.3 (120.8–770.5) 303.7 (115.7–709.7) 570.0 (305.5–299.0) 0.001
hs-C-reactive protein (mg/dL), median (interquartile ranges) 0.26 (0.12–0.58) 0.26 (0.12–0.57) 0.47 (0.13–0.88) 0.077
Interleukin-6 (pg/ml), median (interquartile ranges) 3.1 (1.7–5.5) 3.1 (1.7–5.5) 3.7 (2.1–8.0) 0.209
Reverse Triiodothyronine (ng/ml), median (interquartile ranges) 0.27 (0.22–0.37) 0.27 (0.22–0.36) 0.30 (0.20–0.43) 0.375
Free Triiodothyronine (pg/ml), median (interquartile ranges) 2.80 (2.55–3.06) 2.80 (2.56–3.06) 2.72 (2.24–3.00) 0.036
Thyroid-stimulating hormone (μIU/ml), median (interquartile ranges) 1.8 (1.2–2.6) 1.8 (1.2–2.8) 1.7 (1.4–2.5) 0.875
Free Thyroxine (pg/ml), mean ± SD 13.0 ± 2.5 12.9 ± 2.4 14.6 ± 3.9 <0.001
Total Triiodothyronine (ng/dl), mean ± SD 106.7 ± 19.0 106.8 ± 19.0 104.3 ± 18.3 0.519
Total Thyroxine (μg/dl), mean ± SD 7.1 ± 1.5 7.8 ± 1.5 8.4 ± 1.4 0.042
Follow-up (months), mean ± SD 52.0 ± 29.2 52.5 ± 29.1 43.7 ± 30.6 0.029
  1. NYHA New York Heart Association functional class